

# Racer CC

Sirolimus Eluting Coronary Stent System



Finding ways to the true joys of life

# Racer CC

Sirolimus Eluting Coronary Stent System

**Advanced platform for redefining flexibility  
in tortuous anatomy**

## **Ideal Flexible Approach**


Racer CC offers new generation delivery system with “CC” platform providing unmatched delivery in most tortuous vessels.

## **Enhanced Delivery System**


The customized 2-connector stent design of Racer CC with thinner structural elements confirms for optimal deliverability.

## **Proprietary Hypotube**

The new shaft design offers optimal force transfer with excellent push-ability and kink resistance allowing maneuverability, justifying its use for the most tortuous vessels.



New generation DES providing synergy of biodegradable polymer with microporous surface to enhance optimal performance



### Less Polymeric Load Compared To Other DES



- One million pores per cm<sup>2</sup> with average depth of 2µm ensures optimum drug release with minimum use of polymer
- Top coat with Shellac Resin ensures better polymer-drug binding with negligible polymer flaking during stent expansion
- Drug and polymer are co-released in 6-9 months leaving behind bare metal stent surface

### Better Endothelialisation & Superior Strut Coverage

- Drug polymer matrix coated only on the abluminal side using patented stent coating technology for drug release only to target tissue
- No polymer on the luminal side ensures healthy endothelialisation and reduces the incidence of stent thrombosis

# 10 YEARS CLINICAL DATA OF EFFICACY & SAFETY

In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.




Comparison of clinical outcomes at 10 years in patients treated with new-generation BP-SES versus new-generation PP-EES versus early generation SES.

## Unmatched Safety- In Complex Patients Subset

Long-term outcomes of biodegradable polymer  
Versus durable polymer drug-eluting stents in  
patients with diabetes: a pooled analysis of  
individual patient data from 3 randomized trials



At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of Stent Thrombosis compared to Durable Polymer DES in patients with Diabetes Mellitus.




Secondary safety end point: definite or probable stent thrombosis

Long-term outcomes of biodegradable versus durable  
polymer drug-eluting stents in patients with acute  
ST-segment elevation myocardial infarction: a pooled  
analysis of individual patient data from three randomised trials



At 4 years, Biodegradable Polymer DES Yukon showed significantly lower rates of Stent Thrombosis compared to Durable Polymer DES in patients with Diabetes Mellitus.



Definite or probable stent thrombosis for the pooled population in each of the treatment groups. CI: confidence interval; HR: hazard ratio

# Racer CC

Sirolimus Eluting Coronary Stent System

## PRODUCT MATRIX / ORDERING INFORMATION\*

Stent Ø [mm]	Stent length [mm] & Article number							
	8	12	16	18	21	24	28	32
Ø 2.00	RRCC2008	RRCC2012	RRCC2016	RRCC2018	RRCC2021	RRCC2024	RRCC2028	RRCC2032
Ø 2.50	RRCC2508	RRCC2512	RRCC2516	RRCC2518	RRCC2521	RRCC2524	RRCC2528	RRCC2532
Stent Ø [mm]	Stent length [mm] & Article number							
	8	12	16	18	21	24	28	32
Ø 2.75	RRCC2708	RRCC2712	RRCC2716	RRCC2718	RRCC2721	RRCC2724	RRCC2728	RRCC2732
Ø 3.00	RRCC3008	RRCC3012	RRCC3016	RRCC3018	RRCC3021	RRCC3024	RRCC3028	RRCC3032
Ø 3.50	RRCC3508	RRCC3512	RRCC3516	RRCC3518	RRCC3521	RRCC3524	RRCC3528	RRCC3532
Ø 4.00	RRCC4008	RRCC4012	RRCC4016	RRCC4018	RRCC4021	RRCC4024	RRCC4028	RRCC4032

\* Please contact our Customer Care for available sizes

## COMPLIANCE CHART

Balloon Ø [mm]	Pressure [bar/10 <sup>5</sup> Pa]																
						NP						RBP					
	6	7	8	9	10		11	12	13	14	15		16	17	18	19	20
Ø 2.00	1.83	1.87	1.90	1.93	1.96	2.00	2.03	2.06	2.10	2.13	2.16	2.20	2.23	2.26	2.29		
Ø 2.50	2.33	2.36	2.40	2.43	2.47	2.50	2.53	2.57	2.60	2.64	2.67	2.70	2.74	2.77	2.81		
Ø 2.75	2.58	2.61	2.65	2.68	2.71	2.75	2.78	2.81	2.85	2.88	2.91	2.94	2.98	3.01	3.04		
Ø 3.00	2.81	2.85	2.89	2.92	2.96	3.00	3.04	3.07	3.11	3.15	3.18	3.22	3.26	3.29	3.33		
Ø 3.50	3.29	3.34	3.38	3.42	3.46	3.50	3.55	3.59	3.63	3.67	3.71	3.76	3.80	3.84	3.88		
Ø 4.00	3.75	3.80	3.85	3.90	3.95	4.00	4.06	4.11	4.16	4.21	4.26	4.31	4.36	4.41	4.46		

## TECHNICAL DATA

Cobalt Chromium Alloy (L605)		Entry Profile		0.016" / 0.41 mm	
Crossing Profile (Ø 2.5 mm)	0.035" / 0.89 mm		Proximal Shaft Diameter	1.9 F	
Strut Thickness (Ø 2.5 mm)	0.0027" / 68 µm (SV)		Distal Shaft Diameter	2.7 F	
	0.0031" / 79 µm (MV)		Recommended Guide Wire	0.014"	
Metallic Surface Area	9.1 - 14.9%		Guiding Catheter	min. 5 F	
Balloon Marker Material	Platinum / Iridium				

Manufactured By:  
**Translumina Therapeutics LLP**  
Plot No. 12, Pharmacity, Selaqui,  
Dehradun 248 197  
(Uttarakhand) India  
Drug Manufacturing License No.  
12/UA/SC/P-2016

Registered Office:  
**Translumina Therapeutics LLP**  
Ground Floor, Metro Tower, LSC MOR  
Land,  
New Rajinder Nagar, New Delhi 110 060 -  
India

Under Technological Collaboration With:  
**Translumina GmbH**  
Neue Rottenburger Strasse 50,  
D-72379 Hechingen, Germany

**CMC Medical Devices & Drugs S.L.**  
c/HoracioLengo No 18, CP 29006, Malaga - Spain  
Tel: +34951214054 Fax: +34952330100  
Email: mmateos@cmcmedicaldevices.com  
www.cmcmedicaldevices.com

Customer Care No.: 011-28742874  
Email: info@translumina.in  
Visit www.translumina.in for more details.

Racer CC is a registered trademark of  
Translumina Therapeutics LLP

*Please refer to the Instructions for Use supplied  
with these devices for indications,  
contraindications, adverse effects, suggested  
procedures, warnings and precautions.*